Amsterdam-based OctoPlus says that its hepatitis C drug Locteron demonstrated an antiviral effect in Phase IIa. OctoPlus is developing Locteron with Biolex, which is planning a Phase IIb trial for next year. Release
Amsterdam-based OctoPlus says that its hepatitis C drug Locteron demonstrated an antiviral effect in Phase IIa. OctoPlus is developing Locteron with Biolex, which is planning a Phase IIb trial for next year. Release